AB PA01

Drug Profile

AB PA01

Alternative Names: AB-PA01

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocontrol
  • Developer AmpliPhi Biosciences Corporation
  • Class Antibacterials; Antiglaucomas; Bacteriophages; Quinoxalines; Vasoconstrictors
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Pseudomonal infections

Most Recent Events

  • 02 Oct 2017 Pharmacodynamics data from a preclinical study in Pseudomonas aeruginosa infection released by AmpliPhi Biosciences
  • 14 Aug 2017 AB PA01 is available on a Compassionate Use Programme for the treatment of Pseudomonal infections under emergency IND from US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top